Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry.
Adult
Aged
Aged, 80 and over
Asymptomatic Diseases
Biomarkers
Cohort Studies
Combined Modality Therapy
Female
Humans
Immunoglobulin Light Chains
Male
Middle Aged
Multiple Myeloma
/ diagnosis
Myeloma Proteins
Neoplasm Staging
Patient Outcome Assessment
Population Surveillance
Prognosis
Registries
Sweden
/ epidemiology
Treatment Outcome
Young Adult
amyloidosis
multiple myeloma
plasma cell neoplasms
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
09
09
2019
revised:
05
11
2019
accepted:
06
11
2019
pubmed:
17
11
2019
medline:
20
1
2021
entrez:
17
11
2019
Statut:
ppublish
Résumé
We describe survival in patients with oligo- and non-secretory multiple myeloma (MM). We refer to the whole group as non-measurable MM and compare it with secretory MM. Oligo-secretory MM was defined as M protein in serum <10 g/L and M protein in urine <200 measured as mg/day, mg/liter or mg/mmol creatinine. If patients had no M protein, they were defined as non-secretory. The groups were also subdivided by Free Light Chains (SFLC) level and ratio. Out of 4325 patients with symptomatic MM in the Swedish Myeloma Registry during 2008-2016 eligible for the study, 389 patients (9%) had non-measurable MM. Out of these, 253 patients (6%) had oligo-secretory and 136 (3%) had non-secretory MM. Median survival for secretory MM was 42.7 months, non-measurable MM 40.2 months, oligo-secretory MM 38.6 months, and non-secretory MM 44.6 months. Difference in overall observed survival was non-significant for all groups when compared with secretory MM. Within non-secretory MM, stem cell transplantation (SCT), 95% being auto-SCT, was significant for superior survival in multivariate analysis (HR 0.048. P = .0015). In this population-based study, we found no difference in survival between oligo- or non-secretory MM when compared with secretory MM. SCT appears to be important also for patients with non-secretory disease.
Substances chimiques
Biomarkers
0
Immunoglobulin Light Chains
0
Myeloma Proteins
0
multiple myeloma M-proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
376-382Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
Lonial S, Kaufman JL. Non-secretory myeloma: a clinician's guide. Oncology (Williston Park). 2013;27(9): 924-928, 930.
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
Kyle RA, Larson DR, Therneau TM, et al. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol. 2014;1(1):e28-e36.
Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma. N Engl J Med. 2012;367(6):580-581.
Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13(6):1259-1272.
Cavo M, Galieni P, Gobbi M, et al. Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol. 1985;74(1):27-30.
Corso A, Mangiacavalli S. Non-secretory myeloma: ready for a new definition? Mediterr J Hematol Infect Dis. 2017;9:1-7.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
Chawla SS, Kumar SK, Dispenzieri A, et al. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015;95:57-64.
Kumar S, Perez WS, Zhang MJ, et al. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(10):1134-1140.
Smith DB, Harris M, Gowland E, Chang J, Scarffe JH. Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol. 1986;4(4):307-313.
Terpos E, Apperley JF, Samson D, et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant. 2003;31(3):163-170.
Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570-1571.
Dimopoulos MA, Kastritis E, Terpos E. Non-secretory myeloma: one, two, or more entities? Oncology (Williston Park). 2013;27(9):930-932.
Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica. 2018;103(3):506-513.
Turesson I, Linet MS, Björkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266.
Rajkumar SV. Multiple myeloma: update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(3):226-235.
Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
Statistikmyndigheten SCB (Online). http://www.scb.se/. Accessed May 23, 2019.
The International Myeloma Working group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 2003;121(5):749-757.
Qin XQ, An G, Li ZJ, et al. Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Adv. 2019;3(5):751-760.
Nandakumar B, Gonsalves WI, Francis B, et al. Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience. J Clin Oncol. 2019;37(15_suppl). https://doi.org/10.1200/JCO.2019.37.15_suppl.e19519
Turesson I, Grubb A. Non-secretory or low-secretory myeloma with intracellular kappa chains. Report of six cases and review of the literature. Acta Med Scand. 1978;204(6):445-451.
Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900-2902.